For research use only. Not for therapeutic Use.
Fmoc-Val-Cit-PAB-MMAE (Cat No.:I001343) is a small molecule drug conjugate used in cancer treatment. It is composed of a cytotoxic agent, monomethyl auristatin E (MMAE), linked to a peptide consisting of Fmoc-Val-Cit-PAB (Fmoc = fluorenylmethyloxycarbonyl, PAB = para-aminobenzoic acid) which targets and selectively binds to cancer cells. The MMAE component is then released and induces cancer cell death.
Catalog Number | I001343 |
CAS Number | 1350456-56-2 |
Molecular Formula | C73H104N10O14 |
Purity | ≥95% |
Target | Cytoskeleton |
Solubility | DMSO: ≥ 30 mg/mL |
Storage | Store at -20°C |
IUPAC Name | [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate |
InChI | InChI=1S/C73H104N10O14/c1-15-45(8)63(58(94-13)39-59(84)83-38-24-32-57(83)65(95-14)46(9)66(86)76-47(10)64(85)49-25-17-16-18-26-49)81(11)70(90)61(43(4)5)79-69(89)62(44(6)7)82(12)73(93)97-40-48-33-35-50(36-34-48)77-67(87)56(31-23-37-75-71(74)91)78-68(88)60(42(2)3)80-72(92)96-41-55-53-29-21-19-27-51(53)52-28-20-22-30-54(52)55/h16-22,25-30,33-36,42-47,55-58,60-65,85H,15,23-24,31-32,37-41H2,1-14H3,(H,76,86)(H,77,87)(H,78,88)(H,79,89)(H,80,92)(H3,74,75,91)/t45-,46+,47+,56-,57-,58+,60-,61-,62-,63-,64+,65+/m0/s1 |
InChIKey | RHQGFVOXIOMBMC-UUMMFNFXSA-N |
SMILES | CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46 |
Reference | <p style=/line-height:25px/> |